NovoCure Ltd. (NVCR) PT Lowered to $45 at Wedbush, Following Earnings, Clinical Business Update
Tweet Send to a Friend
Wedbush analyst David Nierengarten lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $45.00 (from $85.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
